Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate CancerGenital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, castration-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, metastatic prostate carcinoma, neoplasm, prostate cancer, prostate disorderActive, not recruitingPhase 22026-07-31NCT02893917

1 results · Page 1 of 1

Swipe the table sideways for more columns.

OrganizationsLinked trials
National Cancer Institute (NCI)3015

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Beth Israel Deaconess Medical CenterBostonUnited States462
Brigham and Women's HospitalBostonUnited States511
Dana-Farber Cancer InstituteBostonUnited States626
Massachusetts General Hospital Cancer CenterBostonUnited States178
Moffitt Cancer CenterTampaUnited States523
Ohio State University Comprehensive Cancer CenterColumbusUnited States548
Smilow Cancer Center/Yale-New Haven HospitalNew HavenUnited States91
UC San Diego Medical Center - HillcrestSan DiegoUnited States57
UC San Diego Moores Cancer CenterLa JollaUnited States199
University of California Davis Comprehensive Cancer CenterSacramentoUnited States299
UPMC Hillman Cancer CenterPittsburghUnited States330
Vanderbilt University/Ingram Cancer CenterNashvilleUnited States259
VCU Massey Comprehensive Cancer CenterRichmondUnited States273
Wayne State University/Karmanos Cancer InstituteDetroitUnited States196
Weisberg Cancer Treatment CenterFarmington HillsUnited States135
Yale UniversityNew HavenUnited States352